肝病患者血清安替比林半衰期的决定因素。
Determinants of serum antipyrine half-lives in patients with liver disease.
作者信息
Branch R A, Herbert C M, Read A E
出版信息
Gut. 1973 Jul;14(7):569-73. doi: 10.1136/gut.14.7.569.
Abstract
Antipyrine has been used as a model drug to investigate the effects of liver disease on drug metabolism in man. A prolongation in antipyrine half-life (T(1/2)) was found in patients with liver disease, patients with chronic liver disease showing a greater increase than those with acute, reversible pathology. The most marked prolongation in T(1/2) was found in association with hypoalbuminaemia and hypoprothrombinaemia, suggesting that the cause for these changes was defective protein synthesis of microsomal enzyme protein. This hypothesis was supported by demonstrating that enzyme-inducing agents, which are known to increase the amount of microsomal enzyme protein, reduced the antipyrine half-life.
摘要
安替比林一直被用作模型药物来研究肝脏疾病对人体药物代谢的影响。在患有肝脏疾病的患者中发现安替比林半衰期（T(1/2)）延长，慢性肝病患者的延长幅度大于急性可逆性病变患者。T(1/2)延长最明显的情况与低白蛋白血症和低凝血酶原血症相关，这表明这些变化的原因是微粒体酶蛋白的蛋白质合成存在缺陷。通过证明已知能增加微粒体酶蛋白量的酶诱导剂可缩短安替比林半衰期，这一假设得到了支持。
相似文献
1
Determinants of serum antipyrine half-lives in patients with liver disease.肝病患者血清安替比林半衰期的决定因素。
Gut. 1973 Jul;14(7):569-73. doi: 10.1136/gut.14.7.569.
2
Antipyrine, paracetamol, and lignocaine elimination in chronic liver disease.慢性肝病中安替比林、对乙酰氨基酚和利多卡因的消除情况。
Br Med J. 1977 May 28;1(6073):1384-7. doi: 10.1136/bmj.1.6073.1384.
3
[Ergometric studies of body tolerance in patients with chronic liver disease].[慢性肝病患者身体耐受性的测力计研究]
Dtsch Med Wochenschr. 1973 Mar 16;98(11):528-31. doi: 10.1055/s-0028-1106854.
4
Impaired elimination of meperidine in patients with liver disease.肝病患者哌替啶消除受损。
Trans Assoc Am Physicians. 1974;87:281-7.
5
Impairment of drug elimination in patients with liver disease.肝病患者药物消除功能受损。
Int J Clin Pharmacol Ther Toxicol. 1985 Jan;23(1):28-32.
6
Lack of effect of zinc supplementation on antipyrine clearance in alcoholic liver disease.补充锌对酒精性肝病患者安替比林清除率无影响。
Eur J Clin Pharmacol. 1996;49(5):397-9. doi: 10.1007/BF00203785.
7
Antipyrine metabolism and liver function in patients treated with high-dose medroxyprogesterone.接受大剂量甲羟孕酮治疗患者的安替比林代谢与肝功能
Biomedicine. 1979 Sep;31(5):135-8.
8
Reduced serum somatomedin activity in patients with chronic liver disease.
Clin Sci Mol Med. 1974 Oct;47(4):359-66. doi: 10.1042/cs0470359.
9
Phenylbutazone and isoniazid metabolism in patients with liver disease in relation to previous drug therapy.
Lancet. 1968 Jun 15;1(7555):1275-9. doi: 10.1016/s0140-6736(68)92292-7.
10
Microsomal enzymes in malnutrition as determined by plasma half life of antipyrine.通过安替比林血浆半衰期测定营养不良中的微粒体酶。
Br Med J. 1977 Feb 26;1(6060):538-40. doi: 10.1136/bmj.1.6060.538.
引用本文的文献
1
Influence of Inflammation on Cytochromes P450 Activity in Adults: A Systematic Review of the Literature.炎症对成人细胞色素P450活性的影响：文献系统综述
Front Pharmacol. 2021 Nov 16;12:733935. doi: 10.3389/fphar.2021.733935. eCollection 2021.
2
Identification of patients with impaired hepatic drug metabolism using a limited sampling procedure for estimation of phenazone (antipyrine) pharmacokinetic parameters.使用有限采样程序估算非那宗（安替比林）药代动力学参数以识别肝药物代谢受损患者。
Clin Pharmacokinet. 1993 Apr;24(4):333-43. doi: 10.2165/00003088-199324040-00006.
3
Disposition kinetics of buspirone in patients with renal or hepatic impairment after administration of single and multiple doses.单次和多次给药后，肾或肝功能损害患者中丁螺环酮的处置动力学。
Eur J Clin Pharmacol. 1994;46(1):41-7. doi: 10.1007/BF00195914.
4
Clinical significance of the trimethadione tolerance test in chronic hepatitis: a useful indicator of hepatic drug metabolizing capacity.三甲双酮耐受试验在慢性肝炎中的临床意义：肝脏药物代谢能力的一项有用指标。
J Gastroenterol. 1995 Aug;30(4):478-84. doi: 10.1007/BF02347564.
5
Further observations on relationships between antipyrine half-life, clearance and volume of distribution: an appraisal of alternative kinetic parameters used to assess the elimination of antipyrine.关于安替比林半衰期、清除率和分布容积之间关系的进一步观察：对用于评估安替比林消除的替代动力学参数的评估。
Clin Pharmacokinet. 1980 May-Jun;5(3):263-73. doi: 10.2165/00003088-198005030-00005.
6
Antipyrine metabolism in cancer patients.
Experientia. 1980 Feb 15;36(2):236-8. doi: 10.1007/BF01953753.
7
Disposition of hexobarbital in intra- and extrahepatic cholestasis in man and the influence of drug metabolism-inducing agents.人肝内和肝外胆汁淤积时己巴比妥的处置及药物代谢诱导剂的影响。
Eur J Clin Pharmacol. 1980;17(3):197-202. doi: 10.1007/BF00561900.
8
Cholestasis and hepatic drug metabolism. Comparison of metabolic clearance rate of antipyrine in patients with intrahepatic or extrahepatic cholestasis.胆汁淤积与肝脏药物代谢。肝内或肝外胆汁淤积患者中安替比林代谢清除率的比较。
Dig Dis Sci. 1981 Aug;26(8):718-22. doi: 10.1007/BF01316861.
9
Plasma high-density lipoproteins and hepatic microsomal enzyme induction. Relation to histological changes in the liver.
Eur J Clin Pharmacol. 1982;23(3):275-82. doi: 10.1007/BF00547568.
10
Impairment of hepatic drug metabolism in patients with acute viral hepatitis.急性病毒性肝炎患者肝脏药物代谢受损。
Eur J Drug Metab Pharmacokinet. 1982 Oct-Dec;7(4):255-8. doi: 10.1007/BF03189627.
本文引用的文献
1
The fate of antipyrine in man.安替比林在人体内的代谢情况。
J Pharmacol Exp Ther. 1950 Jan;98(1):97-104.
2
Persistence of antibiotics in blood of patients with acute renal failure. II. Chloramphenicol and its metabolic products in the blood of patients with severe renal disease or hepatic cirrhosis.急性肾衰竭患者血液中抗生素的持续存在。II. 重症肾病或肝硬化患者血液中的氯霉素及其代谢产物。
J Clin Invest. 1959 Sep;38(9):1498-508. doi: 10.1172/JCI103928.
3
RATE OF METABOLISM OF TOLBUTAMIDE IN TEST SUBJECTS WITH LIVER DISEASE OR WITH IMPAIRED RENAL FUNCTION.患有肝脏疾病或肾功能受损的受试对象中甲苯磺丁脲的代谢率
Am J Med Sci. 1964 Dec;248:657-9. doi: 10.1097/00000441-196412000-00004.
4
Adaptive increases in drug-metabolizing enzymes induced by phenobarbital and other drugs.苯巴比妥及其他药物诱导的药物代谢酶适应性增加。
J Pharmacol Exp Ther. 1960 Sep;130:1-8.
5
Metabolism of drugs in subjects with Laennec's cirrhosis.Laennec 肝硬化患者的药物代谢
Med Exp Int J Exp Med. 1959;1:290-2. doi: 10.1159/000134806.
6
Observations on the metabolic transformation and effects of phenylbutazone in subjects with hepatic disease.
Am J Med Sci. 1954 Jul;228(1):36-9. doi: 10.1097/00000441-195407000-00004.
7
The effect of hepatic blood flow on the hepatic removal rate of oxyphenbutazone in the dog.
J Pharmacol Exp Ther. 1971 Apr;177(1):246-55.
8
Interrelationships of hepatic blood flow, cardiac output, and blood levels of lidocaine in man.人体肝脏血流量、心输出量与利多卡因血药浓度之间的相互关系。
Circulation. 1971 Feb;43(2):205-11. doi: 10.1161/01.cir.43.2.205.
9
Pharmacodynamics of carbenicillin in hepatic and renal failure.羧苄青霉素在肝肾功能衰竭时的药效学
Ann Intern Med. 1970 Aug;73(2):173-8. doi: 10.7326/0003-4819-73-2-173.
10
Genetic control of the phenobarbital-induced shortening of plasma antipyrine half-lives in man.苯巴比妥诱导人体血浆安替比林半衰期缩短的遗传控制。
J Clin Invest. 1969 Dec;48(12):2202-9. doi: 10.1172/JCI106186.
Zotero 插件